Stakeholder Forum 2012

Over 150 people attended IMI's annual Stakeholder Forum at the Husa President Park Hotel  in Brussels, Belgium on Wednesday 30 May 2012.

Videos of the event can be viewed on IMI's YouTube Channel

The event featured:

• presentations on IMI project successes
• an overview of IMI’s recently-launched projects
• an update on IMI’s efforts to simplify procedures
• a debate on IMI’s impact on the pharmaceutical research and development (R&D) landscape
• workshops on the following topics from current and future IMI Calls for proposals:
  - antimicrobial resistance - the final Call text is now available via the 6th Call section
  - vaccines - a draft outline of the indicative Call text is now available on the Future Topics page
  - effectiveness research
• networking opportunities

Agenda

Presentations

Plenary Session

Welcome and introduction
Michel Goldman, Executive Director, IMI

eTOX – Data integration for in silico toxicity prediction
Gerhard Ecker, University of Vienna
Ferran Sanz, IMIM - Universitat Pompeu Fabra

Open PHACTS – the Open Pharmacological Concepts Triple Store
Gerhard Ecker, University of Vienna
Bryn Williams-Jones, Connected Discovery Ltd

Patient involvement in the PROactive project
Pim De Boer, Netherlands Asthma Foundation

IMI Education and Training: www.on-course.eu
Ghazaleh Gouya, Medical University Vienna

Introduction to IMI’s newest projects
Michel Goldman, Executive Director, IMI

Introduction to EUPATI
Nicola Bedlington, European Patients’ Forum

IMI’s simplified procedures
Nathalie Seigneuret, Senior Scientific Project Manager, IMI
Ana Padrão, IT Manager, IMI
Magali Poinot, Legal Manager, IMI

Workshop: Combating Antibiotic Resistance

Introduction
Michel Goldman, Executive Director, IMI

Combating Antibiotic Resistance: New Drugs 4 Bad Bugs (ND4BB)
David Payne, GlaxoSmithKline

IMI’s 6th Call for proposals - Procedures & Practicalities
Nathalie Seigneuret, Scientific Project Manager, IMI
Maria Teresa De Magistris, Principal Scientific Manager, IMI

Workshop: Vaccines & Effectiveness research

Introduction
Ann Martin, Principal Scientific Manager, IMI
Fatiha Sadallah, Principal Scientific Manager, IMI

Building a sustainable framework for rapid assessment of vaccination benefit/risk in Europe
Vincent Bauchau, GSK Biologicals

Incorporating relative effectiveness research into development strategies
Chris Chinn, GlaxoSmithKline, European Pharmaceuticals